These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 9566048)
1. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment. Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine. Daniel WA; Syrek M; Haduch A; Wójcikowski J Pol J Pharmacol; 1998; 50(6):431-42. PubMed ID: 10385926 [TBL] [Abstract][Full Text] [Related]
3. Absorption and excretion of thioridazine and mesoridazine in man. Charalampous KD; Johnson PC; Estevez V Dis Nerv Syst; 1974 Nov; 35(11):494-6. PubMed ID: 17896456 [TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats--a comparison with the pharmacokinetics of imipramine. Daniel W; Syrek M; Janczar L; Boksa J Pol J Pharmacol; 1995; 47(2):127-36. PubMed ID: 8688885 [TBL] [Abstract][Full Text] [Related]
5. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Hartigan-Go K; Bateman DN; Nyberg G; Mårtensson E; Thomas SH Clin Pharmacol Ther; 1996 Nov; 60(5):543-53. PubMed ID: 8941027 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. Salih IS; Thanacoody RH; McKay GA; Thomas SH Clin Pharmacol Ther; 2007 Nov; 82(5):548-54. PubMed ID: 17410120 [TBL] [Abstract][Full Text] [Related]
7. Promazine pharmacokinetics during concurrent treatment with tricyclic antidepressants. Syrek M; Wójcikowski J; Daniel WA Pol J Pharmacol; 1997; 49(6):453-62. PubMed ID: 9566049 [TBL] [Abstract][Full Text] [Related]
8. The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. Daniel WA; Syrek M; Haduch A; Wójcikowski J Exp Toxicol Pathol; 1999 Jul; 51(4-5):309-14. PubMed ID: 10445388 [TBL] [Abstract][Full Text] [Related]
9. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients. Dorado P; Berecz R; Peñas-Lledó EM; de la Rubia A; Llerena A Eur J Clin Pharmacol; 2007 May; 63(5):527-8. PubMed ID: 17345072 [No Abstract] [Full Text] [Related]
10. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine. Eap CB; Souche A; Koeb L; Baumann P Ther Drug Monit; 1991 Jul; 13(4):356-62. PubMed ID: 1780970 [TBL] [Abstract][Full Text] [Related]
11. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317 [TBL] [Abstract][Full Text] [Related]
12. Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations. Greendyke RM; Kanter DR J Clin Psychopharmacol; 1987 Jun; 7(3):178-82. PubMed ID: 3597804 [TBL] [Abstract][Full Text] [Related]
13. Identification of lactams as in vitro metabolites of piperidine-type phenothiazine antipsychotic drugs. Lin G; Chu KW; Damani LA; Hawes EM; Midha KK J Pharm Biomed Anal; 1996 Apr; 14(6):727-38. PubMed ID: 8807548 [TBL] [Abstract][Full Text] [Related]
14. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice. Beland FA Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702 [TBL] [Abstract][Full Text] [Related]
15. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Eap CB; Guentert TW; Schãublin-Loidl M; Stabl M; Koeb L; Powell K; Baumann P Clin Pharmacol Ther; 1996 Mar; 59(3):322-31. PubMed ID: 8653995 [TBL] [Abstract][Full Text] [Related]
16. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors. Niedzwiecki DM; Mailman RB; Cubeddu LX J Pharmacol Exp Ther; 1984 Mar; 228(3):636-9. PubMed ID: 6707914 [TBL] [Abstract][Full Text] [Related]
17. Physiological disposition and biotransformation of (3H) cocaine in acutely and chronically treated rats. Nayak PK; Misra AL; Mulé SJ J Pharmacol Exp Ther; 1976 Mar; 196(3):556-69. PubMed ID: 1263111 [TBL] [Abstract][Full Text] [Related]
18. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study. Chakraborty BS; Midha KK; McKay G; Hawes EM; Hubbard JW; Korchinski ED; Choc MG; Robinson WT J Pharm Sci; 1989 Oct; 78(10):796-801. PubMed ID: 2600782 [TBL] [Abstract][Full Text] [Related]
19. Factors affecting drug concentrations and QT interval during thioridazine therapy. Thanacoody RH; Daly AK; Reilly JG; Ferrier IN; Thomas SH Clin Pharmacol Ther; 2007 Nov; 82(5):555-65. PubMed ID: 17460606 [TBL] [Abstract][Full Text] [Related]
20. Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics. Vital-Herne J; Gerbino L; Kay SR; Katz IR; Opler LA J Clin Psychiatry; 1986 Jul; 47(7):375-9. PubMed ID: 2873133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]